TG Therapeutics TGTX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's operating lease liabilities (current)?
- TG Therapeutics (TGTX) reported operating lease liabilities (current) of $1.82M in Q1 2026.
- How has TG Therapeutics's operating lease liabilities (current) changed year-over-year?
- TG Therapeutics's operating lease liabilities (current) increased by 63.3% year-over-year, from $1.12M to $1.82M.
- What is the long-term trend for TG Therapeutics's operating lease liabilities (current)?
- Over 5 years (2020 to 2025), TG Therapeutics's operating lease liabilities (current) has grown at a -9.0% compound annual growth rate (CAGR), from $1.67M to $1.04M.
- What does operating lease liabilities (current) mean?
- The amount of lease payments due within the next year.
- How do you interpret operating lease liabilities (current)?
- An increase reflects expanding physical footprint or higher lease costs, impacting short-term liquidity requirements.
- How does operating lease liabilities (current) compare across companies?
- This metric is highly comparable across companies that lease their headquarters or research facilities under similar accounting standards.